Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, Follicular × Anti-Infective Agents, Local × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 1 Lymphoma, Follicular 1

Interventions

Rituximab 81 Cyclophosphamide 28 Lenalidomide 25 Bendamustine Hydrochloride 22 Prednisone 18 Vincristine 17 obinutuzumab 16 Doxorubicin 15 fludarabine 13 ibrutinib 12 tazemetostat 9 parsaclisib 8 idelalisib 8 Deoxycholic Acid 8 zanubrutinib 7 tofacitinib 7 Prednisolone 7 venetoclax 6 tisagenlecleucel 5 pembrolizumab 5 ofatumumab 5 duvelisib 5 Gemcitabine 5 Bortezomib 5 ibritumomab tiuxetan 4 aflibercept 4 R-CHOP protocol 4 Methylprednisolone 4 Methotrexate 4 ublituximab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313221 2017-03-15

REFINE

Amgen

Phase 3 Completed

310 enrolled 32 charts

Lymphoma, Follicular, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡